Please use this identifier to cite or link to this item:
|Title:||Treatment of ALK-rearranged non-small cell lung cancer: A review of the landscape and approach to emerging patterns of treatment resistance in the Australian context|
|Authors:||Itchins, M;Chia, Puey Ling;Hayes, SA;Howell, VM;Gill, AJ;Cooper, WA;John, Thomas;Mitchell, P;Millward, M;Clarke, SJ;Solomon, B;Pavlakis, N|
|Citation:||Asia-Pacific Journal of Clinical Oncology 2017; 13 (Supp 3): 3-13|
|Abstract:||Since the identification of anaplastic lymphoma kinase (ALK) gene rearrangements in non-small cell lung cancer (NSCLC) in 2005, the treatment of ALK-rearranged NSCLC (ALK+ NSCLC) has evolved at a rapid pace. This molecularly distinct subset of NSCLC has uniquely important biology, clinicopathologic features and mechanisms of drug resistance which impact on the choice of treatment for a patient with this disease. There are multiple ALK tyrosine kinase inhibitors now available in clinical practice with efficacy data continuing to emerge and guide the optimal treatment algorithm. A detailed search of medical databases and clinical trial registries was conducted to capture all relevant articles on this topic enabling an updated detailed overview of the landscape of management of ALK-rearranged NSCLC.|
Non-small cell lung cancer
Tyrosine kinase inhibitors
|Appears in Collections:||Journal articles|
Files in This Item:
There are no files associated with this item.
Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.